You are viewing the site in preview mode
Skip to main content
| |
Total (n = 180)
|
Rituximab exposed (n = 52)
|
Rituximab unexposed (n = 128)
|
|---|
|
Demographics
|
|
Female, n (%)
|
129 (71.7)
|
43 (82.7)
|
86 (67.2)
|
|
Age, median (IQR)
|
13.0 (10.0, 15.0)
|
13.0 (10.0, 16.0)
|
12.5 (9.0, 15.0)
|
|
Caucasiana, n (%)
|
72 (48.9)
|
14 (29.8)
|
58 (58.0)
|
|
Region, n (%)
|
|
Northeast
|
29 (16.1)
|
9 (17.3)
|
20 (15.6)
|
|
Midwest
|
29 (16.1)
|
8 (15.4)
|
21 (16.4)
|
|
South
|
98 (54.4)
|
30 (57.7)
|
68 (53.1)
|
|
West
|
24 (13.3)
|
5 (9.6)
|
19 (14.8)
|
|
Systemic lupus erythematosus, n (%)
|
2 (1.1)
|
2 (3.9)
|
0 (0.0)
|
|
Sjögren syndrome, n (%)
|
1 (0.6)
|
1 (1.9)
|
0 (0.0)
|
|
ICU status, n (%)
|
31 (17.2)
|
11 (21.2)
|
20 (15.6)
|
|
Length of stay (days), median (IQR)
|
6 (3.0, 12.0)
|
7.0 (3.0, 17.0)
|
6.0 (3.0, 11.0)
|
|
Primary outcome
|
|
Re-hospitalization in 12 months, n (%)
|
66 (36.7)
|
20 (38.5)
|
46 (35.9)
|
|
Secondary outcomes
|
|
Length of re-hospitalization (days), median (IQR)
|
3.0 (1.0, 5.0)
|
2.0 (1.0, 4.0)
|
4.0 (2.0, 6.0)
|
|
Time to re-hospitalization (days), median (IQR)
|
365 (138, 365)
|
365 (138, 365)
|
365 (137, 365)
|
- ICU intensive care unit, IQR interquartile range
- aRace was missing for 33 subjects. Rituximab exposure was defined as having received at least one dose of rituximab during initial hospitalization with a documented ICD-9-CM code for neuromyelitis optica (341.0)
